Drugs / 123I-CMICE-013
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01558362 | Apr → Sep 2012 | coronary artery disorder | Ottawa Heart Institute Research Corporation | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 123I-CMICE-013 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01558362 ↗ |
| Modality | Diagnostic / imaging agent | “alternative radiotracer” NCT01558362 ↗ |
| Route | Intravenous | “2 intravenous doses of drug will be given one week apart.” NCT01558362 ↗ |